TIMOPTIC-XE 0.5 %
TIMOLOL (TIMOLOL MALEATE) : 0.5 % · DIN 02171899 · ELVIUM LIFE SCIENCES
Health Canada status: MARKETED
What is TIMOPTIC-XE?
TIMOPTIC-XE 0.5 % contains TIMOLOL (TIMOLOL MALEATE) : 0.5 %. It is listed in the Health Canada Drug Product Database under DIN 02171899, held by ELVIUM LIFE SCIENCES, supplied as SOLUTION (EXTENDED RELEASE) for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 02-Sep-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TIMOPTIC-XE used for?
Reduction of elevated intraocular pressure.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02171899 |
|---|---|
| Brand name | TIMOPTIC-XE |
| Generic / active ingredient | TIMOLOL (TIMOLOL MALEATE) : 0.5 % |
| Manufacturer | ELVIUM LIFE SCIENCES |
| Strength | 0.5 % |
| Dosage form | SOLUTION (EXTENDED RELEASE) |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01ED01 TIMOLOL |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Sep-2020 |
How is it administered?
One drop in the affected eye(s) once a day. Invert container and shake once before use. Other topical meds should be administered at least 10 minutes before TIMOPTIC-XE.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text sections (Section 11 header present but content truncated), though typically 15-30°C.
How is it supplied?
5 mL dispensers (translucent, high-density polyethylene) with a 2-piece cap assembly.
Contraindications
Hypersensitivity; reactive airway disease (asthma, severe COPD); sinus bradycardia; sick sinus syndrome; sino-atrial block; 2nd/3rd degree AV block; overt cardiac failure; cardiogenic shock.
Warnings and precautions
Systemic absorption may occur. Risk of cardiovascular/pulmonary reactions. May mask hypoglycemia in diabetics or thyrotoxicosis. Caution in patients with COPD or undergoing major surgery.
Is TIMOLOL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code S01ED01 TIMOLOL. 7 of 35 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP-TIMOLOL | 0.5 % | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02447800 |
| SANDOZ TIMOLOL | 0.25 % | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02166712 |
| SANDOZ TIMOLOL | 0.5 % | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02166720 |
| TIMOLOL MALEATE-EX | 0.25 % | SOLUTION (EXTENDED RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02242275 |
| TIMOLOL MALEATE-EX | 0.5 % | SOLUTION (EXTENDED RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02242276 |
| TIMOPTIC | 0.5 % | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | DIN 00451207 |
| APO-TIMOP | 0.25 % | SOLUTION | APOTEX INC | DORMANT | DIN 00755826 |
| APO-TIMOP | 0.5 % | SOLUTION | APOTEX INC | DORMANT | DIN 00755834 |
| APO-TIMOP GEL | 0.25 % | SOLUTION (EXTENDED RELEASE) | APOTEX INC | APPROVED | DIN 02315858 |
| APO-TIMOP GEL | 0.5 % | SOLUTION (EXTENDED RELEASE) | APOTEX INC | DORMANT | DIN 02290812 |
Who else supplies TIMOLOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TIMOLOL appears in 178 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.